Perigon Wealth Management LLC Takes $671,000 Position in West Pharmaceutical Services, Inc. $WST

Perigon Wealth Management LLC bought a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,868 shares of the medical instruments supplier’s stock, valued at approximately $671,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Empowered Funds LLC grew its stake in shares of West Pharmaceutical Services by 16.1% in the 1st quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock valued at $361,000 after purchasing an additional 224 shares during the last quarter. Intech Investment Management LLC raised its stake in shares of West Pharmaceutical Services by 27.7% during the first quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock worth $1,348,000 after purchasing an additional 1,307 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of West Pharmaceutical Services by 14.1% during the first quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after purchasing an additional 157 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of West Pharmaceutical Services by 78.2% during the second quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock worth $98,000 after purchasing an additional 197 shares during the period. Finally, First Trust Advisors LP grew its position in West Pharmaceutical Services by 168.4% in the 2nd quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock valued at $10,137,000 after buying an additional 29,067 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Wolfe Research initiated coverage on shares of West Pharmaceutical Services in a research note on Monday, June 1st. They issued an “outperform” rating and a $375.00 price objective on the stock. Stephens restated an “overweight” rating and issued a $360.00 target price on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Morgan Stanley lifted their target price on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Citigroup boosted their price target on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $352.32 on Thursday. West Pharmaceutical Services, Inc. has a 12-month low of $223.83 and a 12-month high of $386.00. The stock has a market cap of $24.80 billion, a P/E ratio of 45.11, a PEG ratio of 2.42 and a beta of 1.15. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average of $347.64 and a two-hundred day moving average of $298.51.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same period in the prior year, the business earned $1.84 earnings per share. The company’s quarterly revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, research analysts predict that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio is 11.27%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.